Close Menu

NEW YORK – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues rose 11 percent year over year, but the company faced unanticipated reimbursement pressures that negatively impacted its fourth quarter and fiscal year revenues.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.